Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it has received marketing approval from the Ministry of Health, Labour and Welfare of Japan for its peripheral support catheter, Vericor. This approval allows the product to be used in conjunction with a guide wire to enhance peripheral vascular access, assist in reopening chronic total occlusion (CTO) and below-the-knee (BTK) lesions, and reduce the surgical complexity associated with these procedures.
Product Application and Benefits
The Vericor catheter is designed to improve peripheral vascular access, a critical step in many vascular interventions. Its approval in Japan signifies a significant expansion of Acotec’s market reach and underscores the product’s potential to improve patient outcomes in the treatment of peripheral artery disease. The catheter’s ability to assist in reopening CTO and BTK lesions is particularly noteworthy, as these conditions often present significant challenges in vascular surgery.
Reducing Surgical Complexity
The Vericor catheter’s role in reducing the surgical difficulty of complex and BTK lesions is a testament to its innovative design and potential to streamline vascular procedures. This advancement is expected to benefit both patients and medical professionals by enhancing procedural efficiency and safety.-Fineline Info & Tech
